Table 2 Tumor Mutation Burden as Predictor of Non-small Cell Lung Cancer Outcome: OS and PFS Data
Trial/Author (Year) | Subpopulation or Population | Treatment | No. of Patients | OS | PFS | ||
|---|---|---|---|---|---|---|---|
Median (95% CI), Months | HR(95% CI) | Median (95% CI), Months | HR(95% CI) | ||||
CheckMate 026 Carbone et al. (2017) [17] Socinski et al. (2016) [18] | High TMB | NIVO 3 mg/kg Q2W | 47 | 18.3 (11.4-NE) | 1.1 (0.64–1.88) | 9.7 (5.1-NE) | 0.62 (0.38–1.0) |
Platinum-based chemotherapy Q3W | 60 | 18.8 (11.3-NE) | 5.8 (4.2–8.5) | ||||
Low or medium TML | NIVO 3 mg/kg Q2W | 111 | 12.7 (9.9–16.1) | 0.99 (0.71–1.4) | 4.1 (2.8–5.4) | 1.82 (1.3–2.55) | |
Platinum-based chemotherapy Q3W | 94 | 13.2 (9.5–15.2) | 6.9 (5.5–8.6) | ||||
CheckMate 227 Hellmann et al. (2018) [4] | TMB ≥ 10 mutations per mb | NIVO + IPI | 139 | NR | NR | 7.2 (5.5–13.2) | 0.58 (97.5% CI, 0.41–0.81) |
Chemotherapy | 160 | NR | NR | 5.5 (4.4–5.8) | |||
TMB < 10 mutations per mb | NIVO + IPI | 191 | NR | NR | 3.2 (2.7–4.3) | 1.07 (0.84–1.35) | |
Chemotherapy | 189 | NR | NR | 5.5 (4.3–5.6) | |||
OAKa Rittmeyer et al. (2017) [6] Gadgeel et al. (2017) [19] Barlesi et al. (2016) [20] Hida et al. (2018) [21] Gandara et al. (2017) [22] | TMB ≥ 10 | ATEZO vs. DTX | 251 | NR | 0.69 (NR) | NR | 0.73 (NR) |
TMB ≥ 16 |  | 158 | NR | 0.64 (NR) | NR | 0.65 (NR) | |
TMB ≥ 20 | 105 | NR | 0.65 (NR) | NR | 0.61 (NR) | ||
POPLARa Fehrenbacher et al. (2016) [23] Smith et al. (2016) [24] Mazieres et al. (2016) [25] Vansteenkiste et al. (2015) [26] Spira et al. (2015) [27] Gandara et al. (2017) [22] | TMB ≥ 10 | ATEZO vs. DTX | 96 | NR | 0.59 (NR) | NR | 0.68 (NR) |
TMB ≥ 16 | 63 | NR | 0.56 (NR) | NR | 0.57 (NR) | ||
TMB ≥ 20 | 42 | NR | 0.51 (NR) | NR | 0.58 (NR) | ||
Yaghmour (2016) [28] | TML: top quintile | ≥ First line, NIVO or IPI | 50 (overall patients) | NR | 3.29 (0.75–25.53) | NR | NR |
TML: other quintiles | NR | NR | NR | ||||
B-F1RST Velcheti (2018) [29] | Blood-based TMB ≥ 12 | ATEZO | 22 | NR | NR | 3 | 0.95 (90% CI, 0.55–1.63) |
Blood-based TMB < 12 | 36 | NR | NR | 3.2 | |||
Blood-based TMB ≥ 14 | 14 | NR | NR | 3.4 | 0.73 (90% CI, 0.39–1.39) | ||
Blood-based TMB < 14 | 44 | NR | NR | 3.2 | |||
Blood-based TMB ≥ 16 | 11 | NR | NR | 9.5 | 0.49 (90% CI, 0.23–1.04) | ||
Blood-based TMB < 16 | 47 | NR | NR | 2.8 | |||
Blood-based TMB ≥ 20 | 8 | NR | NR | 9.5 | 0.23 (90% CI, 0.08–0.62) | ||
Blood-based TMB < 20 | 50 | NR | NR | 2.7 | |||